A Phase 2 interventional study of Anisodine Hydrobromide and Anisodine Hydrobromide Placebo in Acute Ischemic Stroke, sponsored by Capital Medical University. Recruiting at 13 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Capital Medical University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Ischemic Stroke by Capital Medical University — 20 open to participants now, 25 under way, 10 of them phase 3. Ischemic Stroke · Capital Medical University.
Among the 45 studies in Ischemic Stroke by Capital Medical University, this one is the 21st largest by planned enrollment of the 39 interventional ones that give a count, is one of 10 that started in 2026, is one of 7 in phase 2, reaches primary completion later than 11 of the 24 other live ones, and was the 45th registered.
2,617 studies on the registry are indexed under Ischemic Stroke; 976 are open to participants now.
Browse Ischemic Stroke studies →20 of the 45 studies in Ischemic Stroke by Capital Medical University are open now, in 1 country. Recruiting first, the newest first:
Capital Medical University · Sites in China
Ages 18+
Capital Medical University · Sites in China
Ages 18+
Capital Medical University · Sites in China
Ages 18+
Capital Medical University · Sites in China
Ages 40–80
Capital Medical University · Sites in China
Ages 18–80
By country, each count listing its studies:
Of the 661 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 12
First in 2017; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 204 is above the median of 120 across 1,780 interventional studies indexed under Ischemic Stroke.
Median enrollment 208 across the 39 interventional studies, 550 across the 6 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Capital Medical University is the lead sponsor of 296 studies on the registry; 90 are open to participants now.
13 of the studies in Ischemic Stroke by Capital Medical University that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559241Phase 3Capital Medical UniversityRemote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy（RECAST-MT） | 2026-11 |
| NCT06615726Phase 3Capital Medical UniversityRegular Physical Exercise in Patients With Symptomatic Intracranial Arterial Stenosis | 2026-11-19 |
| NCT07509645Phase 3Capital Medical UniversityEfficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke | 2027-04-20 |
| NCT07263308Phase 3Capital Medical UniversityAlbumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2 | 2027-06-20 |
| NCT06666764Phase 3Capital Medical UniversityNormobaric Oxygen in AIS Transferred for EVT | 2027-10 |
Add all 13 to your calendar (.ics) → With an account.
Among the 45 studies in Ischemic Stroke by Capital Medical University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase 2, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of anisodine hydrobromide in patients with acute ischemic stroke undergoing endovascular thrombectomy.
Eligible participants will be randomly assigned to receive anisodine hydrobromide or matching placebo in addition to standard care, with efficacy and safety assessed during follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive anisodine hydrobromide combined with endovascular thrombectomy.
Drug: Anisodine Hydrobromide
Participants will receive placebo combined with endovascular thrombectomy.
Drug: Anisodine Hydrobromide Placebo
Anisodine hydrobromide, 2 mg per dose, diluted in 0.9% sodium chloride solution and administered by intravenous infusion twice daily for a total of 14 doses.
An equivalent volume of 0.9% sodium chloride solution, administered by intravenous infusion twice daily for a total of 14 doses.
Cerebral Infarct Volume on Day 8
Time frame: Day 8
NIHSS Score at 24 Hours
Time frame: 24 hours
NIHSS Score on Day 8
The NIHSS ranges from 0 to 42, with higher scores indicating greater neurological impairment and a worse outcome.
Time frame: Day 8
Change in NIHSS Score From Baseline to Day 8
The NIHSS ranges from 0 to 42. Change is calculated as the Day 8 score minus the baseline score.
Time frame: Baseline to Day 8
mRS Score of 0-1 at 90 Days
The mRS ranges from 0 to 6, with higher scores indicating greater disability or death.
Time frame: 90 Days
mRS Score of 0-2 at 90 Days
The mRS ranges from 0 to 6, with higher scores indicating greater disability or death
Time frame: 90 Days
Distribution of mRS scores at 90 Days
The mRS ranges from 0 to 6, with higher scores indicating greater disability or death.
Time frame: 90 Days
EQ-5D-5L at 90 Days
The EQ-5D-5L index score ranges from -0.391 to 1.000 using the Chinese value set, with higher scores indicating better health-related quality of life.
Time frame: 90 Days
Barthel Index Score of 95-100 at 90 Days
The Barthel Index ranges from 0 to 100, with higher scores indicating greater independence in activities of daily living.
Time frame: 90 Days
Neurological Deterioration Within 24 Hours
an increase of ≥4 points in the NIHSS score from baseline
Time frame: Within 24 hours
Symptomatic Intracranial Hemorrhage Within 8 Days
Time frame: Within 8 Days
All Cause Mortality at 90 Days
Time frame: Within 90 days
Intracranial Hemorrhage Within 8 Days
Time frame: Within 8 Days
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Dec 2026, 3 months after the start.
Of 83 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 3 months is below that.
Counting every sponsor, half of 124 studies reached it within 28 months; a quarter within 15 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anisodine